By Adjunct Professor Michael Leonard Friedlander

Journal articles

FRIEDLANDER ML; SIMS K; KEARSLEY JH, 1983, 'IMPAIRMENT OF RECALL IMPROVES TOLERANCE OF CYTO-TOXIC CHEMOTHERAPY', LANCET, 2, pp. 686 - 686

Tattersall MH; Friedlander ML, 1982, 'Cost considerations in cancer chemotherapy.', Australian Health Review A Publication of the Australian Hospital Association, 5, pp. 21 - 24

Friedlander ML; Tattersall MHN, 1982, 'Counting the costs of cancer therapy', European Journal of Cancer and Clinical Oncology, 18, pp. 1237 - 1241, http://dx.doi.org/10.1016/0277-5379(82)90124-9

Raghavan D; Coates A; Friedlander M, 1982, 'Mitoxantrone (XAN): Progress in a phase ii trial in Sydney, Australia', Proceedings of the American Society of Clinical Oncology, Vol. 1

Friedlander ML; Halley JBW; Sinosich MJ; Coates A, 1982, 'Pulmonary Pseudotumours Following Chemotherapy for Endodermal Sinus Tumour of the Ovary', Australian and New Zealand Journal of Obstetrics and Gynaecology, 22, pp. 110 - 112, http://dx.doi.org/10.1111/j.1479-828X.1982.tb01417.x

Friedlander M; Tattersall MHN, 1981, 'Postoperative radiotherapy in breast cancer', British Medical Journal Clinical Research Ed, 282, pp. 2133 - 2134, http://dx.doi.org/10.1136/bmj.282.6282.2133-d

Friedlander M; Kearsley JH; Tattersall MHN, 1981, 'ORAL LORAZEPAM TO IMPROVE TOLERANCE OF CYTOTOXIC THERAPY', Lancet, 317, pp. 1316 - 1317, http://dx.doi.org/10.1016/S0140-6736(81)92489-2

FRIEDLANDER M; KEARSLEY JH; TATTERSALL MHN, 1981, 'ORAL LORAZEPAM TO IMPROVE TOLERANCE OF CYTO-TOXIC THERAPY', LANCET, 1, pp. 1316 - 1317

Friedlander ML, 1980, 'AMINOGLUTETHIMIDE AND PROSTATIC CANCER', Lancet, 316, pp. 1373, http://dx.doi.org/10.1016/S0140-6736(80)92440-X

FRIEDLANDER ML, 1980, 'AMINOGLUTETHIMIDE AND PROSTATIC-CANCER', LANCET, 2, pp. 1373 - 1373, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1980KU80600049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers

Phillips K-A; Kotsopoulos J; Domchek S; Chamberlain J; Bassett J; Aeilts A; Andrulis I; Buys S; Cui W; Daly M; Eisen A; Foulkes W; Friedlander M; Gronwald J; Hopper J; John E; Karlan B; Kim R; Lubiński J; Metcalfe K; Nathanson K; Singer CF; Symecko H; Tung N; Narod S; Terry MB; Milne R, 2024, 'Abstract PS10-01: Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Pathogenic Variants in BRCA1 and BRCA2', in Cancer Research, American Association for Cancer Research (AACR), pp. ps10-01-ps10-01, http://dx.doi.org/10.1158/1538-7445.sabcs23-ps10-01

Naidoo M; Mcnally O; Scott C; Friedlander M; Cohen P; Perera S; Brand A; Richardson G; Bunting M; Mohan R; Oehler M; Hyde S; Jobling T; Farrell R; Evans S; Rome R; Zalcberg J, 2024, 'EV306/#612  Patterns of ovarian cancer care and overall survival in Australia: a prospective study from the National Gynae-Oncology Registry (NGOR)', in International Journal of Gynecological Cancer, Elsevier, pp. a240, http://dx.doi.org/10.1136/ijgc-2024-igcs.425

Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin LR; Ananda S; Shannon CM; Friedlander M; Warton K; Ford C, 2023, 'Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Ngoi NYL; Sun H; Choi CH; Heong V; Ow SGW; Chay WY; Kim HS; Goss G; Goh JC; Lin M; Lim D; Kim J-W; Friedlander M; Tai BC; Kim K; Tan DSP, 2023, 'Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician's choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Deva S; Millward M; Friedlander M; Gan HK; Hovarth LG; Lee J-S; Hill A; Sandhu S; Liang L; Shi J; Zhang Y; Shi Y; Ma X; Wu X; Shen Z; Desai J, 2022, 'The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans, 08 April 2022 - 13 April 2022

Konstantinopoulos P; Gonzalez-Martin A; Cruz F; Friedlander M; Glasspool R; Lorusso D; Marth C; Monk B; Kim J-W; Ajipa O; Su F; Han YU; Matulonis U, 2022, 'TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer', in International Journal of Gynecological Cancer, Elsevier, pp. a238, http://dx.doi.org/10.1136/ijgc-2022-igcs.539

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Abstract 1045: Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy', in Cancer Research, American Association for Cancer Research (AACR), pp. 1045 - 1045, http://dx.doi.org/10.1158/1538-7445.am2021-1045

Xu X; Wang Y; Bryce N; Tang K; Meagher NS; Kang EY; Kelemen LE; Kobel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 10 April 2021 - 21 May 2021

Wildiers H; Ayoub J-P; Friedlander M; Kaufman B; Arun BK; Han HS; Puhalla SL; Maag D; Feng D; Ratajczak CK; Bach BA; Diéras V, 2021, 'Abstract PS11-03: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germline BRCA1 or BRCA2 mutations from the phase 3 BROCADE3 trial', in Cancer Research, American Association for Cancer Research (AACR), pp. ps11-03-ps11-03, http://dx.doi.org/10.1158/1538-7445.sabcs20-ps11-03

Arun BK; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla SL; Bach BA; Dudley M; Ratajczak CK; Maag D; Diéras V, 2020, 'Abstract PD4-01: First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic g BRCA -associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial', in Cancer Research, American Association for Cancer Research (AACR), pp. pd4-01-pd4-01, http://dx.doi.org/10.1158/1538-7445.sabcs19-pd4-01

Ayoub J-P; Friedlander ML; Dieras VC; Wildiers H; Arun B; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Kundu MG; Wu M; Ratajczak C; Maag D; Kaufman B, 2020, '140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial', in Annals of Oncology, Elsevier, pp. s65, http://dx.doi.org/10.1016/j.annonc.2020.03.241

Friedlander ML; Moore K; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Holmes E; Lowe ES; Disilvestro P, 2020, '234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in Annals of Oncology, Elsevier, pp. s1334, http://dx.doi.org/10.1016/j.annonc.2020.10.228

Colombo N; Bradley W; Moore K; González-Martín A; Scambia G; Oaknin A; Friedlander M; Lowe E; Rowe P; Disilvestro P, 2020, '392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study', in International Journal of Gynecological Cancer, Elsevier, pp. a76 - a77, http://dx.doi.org/10.1136/ijgc-2020-esgo.130

Sivakumaran T; Krasovitsky M; Freimund A; Chen Lee K; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2020, '402 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in International Journal of Gynecological Cancer, Elsevier BV, pp. A166 - A167, http://dx.doi.org/10.1136/ijgc-2020-igcs.347

Sivakumaran T; Krasovitsky M; Lee YC; Norris C; Friedlander M, 2020, '403 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in International Journal of Gynecological Cancer, Elsevier, pp. a167, http://dx.doi.org/10.1136/ijgc-2020-igcs.348

Banerjee S; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; Martín AG; Aghajanian C; Bradley W; Holmes E; Lowe ES; DiSilvestro P, 2020, 'Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1', in Annals of Oncology, Elsevier, pp. s613, http://dx.doi.org/10.1016/j.annonc.2020.08.950

Yoon W-H; Kok PS; Marschner I; Lord S; Friedlander M; Lee CK, 2020, 'Objective response rate as an intermediate surrogate endpoint to predict overall survival at 12 months', in Annals of Oncology, Elsevier, pp. s715, http://dx.doi.org/10.1016/j.annonc.2020.08.1162

Swisher EM; Coleman RL; Bookman MA; Brady MF; Fleming GF; Friedlander M; Cunningham MJ; Tewari KS; Edraki B; Moxley K; Mantia-Smaldone GM; Ratajczak C; Dinh MH; Sullivan DM; McClain S; Okubo S; Steffensen KD; Aghajanian C, 2020, 'Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 20 - 21, http://dx.doi.org/10.1016/j.ygyno.2020.06.040

Macdonald C; Mazza D; Hickey M; Hunter M; Keogh LA; Jones SC; Saunders C; Nesci S; Milne RL; McLachlan SA; Hopper J; Friedlander M; Emery J; Phillips KA, 2020, 'The cognitive, affective, social and environmental drivers of inappropriate ovarian cancer screening: A survey of women and their clinicians using the theoretical domains framework', in Annals of Oncology, Elsevier, pp. s958, http://dx.doi.org/10.1016/j.annonc.2020.08.2057

Meiser B; Gleeson M; Kentwell M; Do J; Nevin S; Taylor N; Barlow-Stewart K; Kirk J; James P; Scott CL; Williams R; Gamet K; Burke J; Murphy M; Antill Y; Pearn A; Pachter N; Ebzery C; Poplawski N; Friedlander M; Tucker K, 2020, 'The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 62 - 62

Sivakumaran T; Krasovitsky M; Lee YC; Norris C; Friedlander M, 2020, 'TREATMENT PATTERNS POST PARP INHIBITOR IN EPITHELIAL OVARIAN CANCER PATIENTS: RESULTS FROM AN AUSTRALIAN, RETROSPECTIVE, MULTI-INSTITUTE COHORT STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. A167 - A167

Sun Y; Friedlander M, 2019, 'One-shot atomic detection', in 2019 IEEE 8TH INTERNATIONAL WORKSHOP ON COMPUTATIONAL ADVANCES IN MULTI-SENSOR ADAPTIVE PROCESSING (CAMSAP 2019), IEEE, FRANCE, Guadeloupe, pp. 1 - 5, presented at 8th IEEE International Workshop on Computational Advances in Multi-Sensor Adaptive Processing (CAMSAP), FRANCE, Guadeloupe, 15 December 2019 - 18 December 2019, http://dx.doi.org/10.1109/camsap45676.2019.9022441

Friedlander ML, 2019, 'Do all patients with recurrent ovarian cancer need systemic therapy?', in Cancer, pp. 4602 - 4608, http://dx.doi.org/10.1002/cncr.32476

Piskorz A; Robertson D; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; McNeish IA; Swisher E; Wason J; Brenton JD, 2019, 'Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. gmm-048-gmm-048, http://dx.doi.org/10.1158/1557-3265.ovcasymp18-gmm-048

Desai J; Markman B; Friedlander M; Gan H; Horvath L; Townsend A; Millward M; Jameson M; Yen C-J; Hou M-M; Hou J; Wu J; Liang L; Deva S, 2019, 'Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', American Association for Cancer Research (AACR), pp. ct084 - ct084, presented at Clinical Trials, http://dx.doi.org/10.1158/1538-7445.sabcs18-ct084

Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P, 2019, 'Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial', in International Journal of Gynecological Cancer, Elsevier, pp. a14 - a15, http://dx.doi.org/10.1136/ijgc-2019-esgo.17

Deva S; Lee J-S; Lin C-C; Yen C-J; Millward M; Chao Y; Keam B; Jameson M; Hou M-M; Kang Y-K; Markman B; Lu C-H; Rau K-M; Lee K-H; Horvath L; Friedlander M; Hill A; Wu J; Hou J; Desai J, 2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, presented at ESMO Immuno-Oncology Congress, SWITZERLAND, Geneva, 13 December 2018 - 16 December 2018

Sandhu S; Hill A; Gan H; Friedlander M; Voskoboynik M; Barlow P; Townsend A; Song J; Zhang Y; Liang L; Desai J, 2018, 'Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SWITZERLAND, Geneva, pp. 28 - 28, presented at ESMO Immuno-Oncology Congress, SWITZERLAND, Geneva, 13 December 2018 - 16 December 2018

Goh JC; Baron-Hay S; Bonaventura T; Buck M; Dean A; Friedlander M; Gao B; Mileshkin L; Oehler MK; Steer C; Vi N; Goble S; Grechko N; Monk BJ; Kristeleit RS, 2018, 'ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 196 - 196, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200343&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, GERMANY, Munich, pp. 727 - 727, presented at 43rd ESMO Congress (ESMO), GERMANY, Munich, 19 October 2018 - 23 October 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277305017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Antill Y; Barlow-Stewart K; Friedlander M; Meiser B; Do J; Nevin S; Gleeson M; Kentwell M; Tucker K; Taylor N; Kirk J, 2018, 'Changing a nation: The development and evaluation of a training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. 202 - 203, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471153100137&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; González-Martín A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2018, 'Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial', in Annals of oncology : official journal of the European Society for Medical Oncology, pp. viii727, http://dx.doi.org/10.1093/annonc/mdy424.041

Mileshkin L; Sivakumaran T; Grant P; Na L; Friedlander M; Webb P; Au-Yeung G, 2018, 'COMPARING THE IMPACT OF DOSE REDUCTIONS/ DELAYS ON OVARIAN CANCER OUTCOMES USING THREE WEEKLY OR DOSE DENSE CARBOPLATIN/ PACLITAXEL REGIMENS IN THE NATIONAL PROSPECTIVE OPAL COHORT', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, BMJ PUBLISHING GROUP, pp. 770 - 770, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471152401334&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Webb PM; Beesley V; deFazio A; Obermair A; Grant PT; Nagle C; Friedlander M, 2018, 'The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.155

Webb PM; deFazio A; Obermair A; Grant PT; Friedlander M; Beesley V; Nagle C, 2018, 'The Ovarian cancer Prognosis And Lifestyle (OPAL) study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.88

Webb PM; Beesley V; Nagle C; Grant PT; deFazio A; Obermair A; Friedlander M, 2018, 'When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2018 - 05 June 2018, http://dx.doi.org/10.1200/JCO.2018.36.7_suppl.172

Vergote I; Hanker LC; Floquet A; Rau J; Kim J-W; Ortega Izquierdo E; Friedlander M; Pignata S; Fujiwara K; Colombo N; Mirza MR; Monk BJ; Mörtl M; Calvert P; Herzog TJ; Jackisch C; Meunier J; Lee J-Y; Belau AK; Du Bois A, 2018, 'AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), pp. 5518 - 5518, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.5518

Friedlander M; Chan JK; Java J; Armstrong DK; Markman M; Herzog TJ; Monk BJ; Backes FJ; Secord AA; Bonebrake AJ; Rose PG; Tewari KS; Mannel RS; Lentz SS; Geller MA; Copeland LJ, 2018, 'Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), pp. 5556 - 5556, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.5556

Sivakumaran T; Mileshkin LR; Grant PT; Friedlander M; Webb PM; Au-Yeung G, 2018, 'Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.5568

Back to profile page